Microbiotica was only founded in 2016 but is already collaring a European lead in microbiome technology.
It is researching the body’s trillions of resident bacteria to improve diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
In October 2018 the company attracted £4 million of new investment from Paris-based Seventure Partners to take its early funding haul to £12m. Seventure Partners, a specialist investor in the microbiome, joined founding backers Cambridge Innovation Capital and IP Group by committing the new £4m.
Microbiotica, based at the Wellcome Genome Campus was founded to develop transformational technology developed at the Sanger Institute. The UK business reports rapid progress in developing a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling the precise association of bacteria to function at clinical trial scale.
The company was founded by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, FRS. It has already engineered a strategic collaboration with Genentech, a member of the Roche Group, in the field of inflammatory bowel disease as well as with University of Adelaide to develop a defined product for ulcerative colitis.